vs
芝商所(CME)与英格索兰(IR)财务数据对比。点击上方公司名可切换其他公司
英格索兰的季度营收约是芝商所的1.1倍($2.1B vs $1.9B),英格索兰净利率更高(12.7% vs 0.1%,领先12.7%),芝商所同比增速更快(14.5% vs 10.1%),过去两年英格索兰的营收复合增速更高(11.9% vs 10.8%)
芝商所是总部位于美国伊利诺伊州芝加哥的金融服务企业,为全球规模最大的金融衍生品交易所运营商,旗下拥有芝加哥商品交易所、芝加哥期货交易所、纽约商业交易所、纽约商品交易所等交易平台,覆盖农产品、货币、能源等品类交易,同时持有标普道琼斯指数27%的股权。
英格索兰是一家美国跨国企业,主营流体生产及工业产品业务。公司于2020年2月由原英格索兰plc的工业业务板块分拆后与加德纳丹佛合并组建,旗下拥有40多个品牌,产品覆盖全球所有主要市场。
CME vs IR — 直观对比
营收规模更大
IR
是对方的1.1倍
$1.9B
营收增速更快
CME
高出4.3%
10.1%
净利率更高
IR
高出12.7%
0.1%
两年增速更快
IR
近两年复合增速
10.8%
损益表 — Q1 FY2026 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $1.9B | $2.1B |
| 净利润 | $1.2M | $266.1M |
| 毛利率 | — | 42.6% |
| 营业利润率 | 0.1% | 18.7% |
| 净利率 | 0.1% | 12.7% |
| 营收同比 | 14.5% | 10.1% |
| 净利润同比 | 20.7% | 15.8% |
| 每股收益(稀释后) | — | $0.67 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
CME
IR
| Q1 26 | $1.9B | — | ||
| Q4 25 | $1.6B | $2.1B | ||
| Q3 25 | $1.5B | $2.0B | ||
| Q2 25 | $1.7B | $1.9B | ||
| Q1 25 | $1.6B | $1.7B | ||
| Q4 24 | $1.5B | $1.9B | ||
| Q3 24 | $1.6B | $1.9B | ||
| Q2 24 | $1.5B | $1.8B |
净利润
CME
IR
| Q1 26 | $1.2M | — | ||
| Q4 25 | $1.2B | $266.1M | ||
| Q3 25 | $908.0M | $244.1M | ||
| Q2 25 | $1.0B | $-115.3M | ||
| Q1 25 | $956.2M | $186.5M | ||
| Q4 24 | $874.6M | $229.8M | ||
| Q3 24 | $912.8M | $221.6M | ||
| Q2 24 | $883.2M | $185.0M |
毛利率
CME
IR
| Q1 26 | — | — | ||
| Q4 25 | — | 42.6% | ||
| Q3 25 | — | 43.7% | ||
| Q2 25 | — | 43.7% | ||
| Q1 25 | — | 44.6% | ||
| Q4 24 | — | 42.9% | ||
| Q3 24 | — | 43.8% | ||
| Q2 24 | — | 43.9% |
营业利润率
CME
IR
| Q1 26 | 0.1% | — | ||
| Q4 25 | 61.8% | 18.7% | ||
| Q3 25 | 63.3% | 19.2% | ||
| Q2 25 | 66.7% | 4.0% | ||
| Q1 25 | 67.5% | 17.6% | ||
| Q4 24 | 62.1% | 20.0% | ||
| Q3 24 | 64.6% | 19.1% | ||
| Q2 24 | 65.3% | 15.1% |
净利率
CME
IR
| Q1 26 | 0.1% | — | ||
| Q4 25 | 71.7% | 12.7% | ||
| Q3 25 | 59.1% | 12.5% | ||
| Q2 25 | 60.6% | -6.1% | ||
| Q1 25 | 58.2% | 10.9% | ||
| Q4 24 | 57.3% | 12.1% | ||
| Q3 24 | 57.6% | 11.9% | ||
| Q2 24 | 57.6% | 10.2% |
每股收益(稀释后)
CME
IR
| Q1 26 | — | — | ||
| Q4 25 | $3.24 | $0.67 | ||
| Q3 25 | $2.49 | $0.61 | ||
| Q2 25 | $2.81 | $-0.29 | ||
| Q1 25 | $2.62 | $0.46 | ||
| Q4 24 | $2.40 | $0.57 | ||
| Q3 24 | $2.50 | $0.54 | ||
| Q2 24 | $2.42 | $0.45 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | $2.4B | $1.2B |
| 总债务越低越好 | $3.4B | $4.8B |
| 股东权益账面价值 | — | $10.1B |
| 总资产 | $202.0B | $18.3B |
| 负债/权益比越低杠杆越低 | — | 0.47× |
8季度趋势,按日历期对齐
现金及短期投资
CME
IR
| Q1 26 | $2.4B | — | ||
| Q4 25 | $4.5B | $1.2B | ||
| Q3 25 | $2.6B | $1.2B | ||
| Q2 25 | $2.1B | $1.3B | ||
| Q1 25 | $1.5B | $1.6B | ||
| Q4 24 | $3.0B | $1.5B | ||
| Q3 24 | $2.4B | $1.4B | ||
| Q2 24 | $1.9B | $1.1B |
总债务
CME
IR
| Q1 26 | $3.4B | — | ||
| Q4 25 | — | $4.8B | ||
| Q3 25 | — | $4.8B | ||
| Q2 25 | — | $4.8B | ||
| Q1 25 | — | $4.8B | ||
| Q4 24 | — | $4.8B | ||
| Q3 24 | — | $4.8B | ||
| Q2 24 | — | $4.8B |
股东权益
CME
IR
| Q1 26 | — | — | ||
| Q4 25 | $28.7B | $10.1B | ||
| Q3 25 | $28.2B | $10.1B | ||
| Q2 25 | $27.7B | $10.1B | ||
| Q1 25 | $27.0B | $10.5B | ||
| Q4 24 | $26.5B | $10.2B | ||
| Q3 24 | $28.2B | $10.3B | ||
| Q2 24 | $27.6B | $10.0B |
总资产
CME
IR
| Q1 26 | $202.0B | — | ||
| Q4 25 | $198.4B | $18.3B | ||
| Q3 25 | $187.1B | $18.2B | ||
| Q2 25 | $179.9B | $18.1B | ||
| Q1 25 | $157.8B | $18.4B | ||
| Q4 24 | $137.4B | $18.0B | ||
| Q3 24 | $137.8B | $18.2B | ||
| Q2 24 | $123.4B | $17.8B |
负债/权益比
CME
IR
| Q1 26 | — | — | ||
| Q4 25 | — | 0.47× | ||
| Q3 25 | — | 0.47× | ||
| Q2 25 | — | 0.47× | ||
| Q1 25 | — | 0.45× | ||
| Q4 24 | — | 0.47× | ||
| Q3 24 | — | 0.47× | ||
| Q2 24 | — | 0.48× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | — | $499.0M |
| 自由现金流经营现金流 - 资本支出 | — | $461.5M |
| 自由现金流率自由现金流/营收 | — | 22.1% |
| 资本支出强度资本支出/营收 | — | 1.8% |
| 现金转化率经营现金流/净利润 | — | 1.88× |
| 过去12个月自由现金流最近4个季度 | — | $1.2B |
8季度趋势,按日历期对齐
经营现金流
CME
IR
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $499.0M | ||
| Q3 25 | $968.1M | $354.6M | ||
| Q2 25 | $1.1B | $245.7M | ||
| Q1 25 | $1.1B | $256.4M | ||
| Q4 24 | $1.0B | $526.2M | ||
| Q3 24 | $1.0B | $404.0M | ||
| Q2 24 | $776.9M | $304.9M |
自由现金流
CME
IR
| Q1 26 | — | — | ||
| Q4 25 | $1.1B | $461.5M | ||
| Q3 25 | $949.7M | $325.5M | ||
| Q2 25 | $1.0B | $210.4M | ||
| Q1 25 | $1.1B | $222.7M | ||
| Q4 24 | $991.7M | $490.9M | ||
| Q3 24 | $973.2M | $374.3M | ||
| Q2 24 | $758.7M | $283.1M |
自由现金流率
CME
IR
| Q1 26 | — | — | ||
| Q4 25 | 66.8% | 22.1% | ||
| Q3 25 | 61.8% | 16.6% | ||
| Q2 25 | 61.5% | 11.1% | ||
| Q1 25 | 67.1% | 13.0% | ||
| Q4 24 | 65.0% | 25.9% | ||
| Q3 24 | 61.4% | 20.1% | ||
| Q2 24 | 49.5% | 15.7% |
资本支出强度
CME
IR
| Q1 26 | — | — | ||
| Q4 25 | 2.0% | 1.8% | ||
| Q3 25 | 1.2% | 1.5% | ||
| Q2 25 | 1.1% | 1.9% | ||
| Q1 25 | 0.9% | 2.0% | ||
| Q4 24 | 1.7% | 1.9% | ||
| Q3 24 | 1.9% | 1.6% | ||
| Q2 24 | 1.2% | 1.2% |
现金转化率
CME
IR
| Q1 26 | — | — | ||
| Q4 25 | 0.96× | 1.88× | ||
| Q3 25 | 1.07× | 1.45× | ||
| Q2 25 | 1.03× | — | ||
| Q1 25 | 1.17× | 1.37× | ||
| Q4 24 | 1.16× | 2.29× | ||
| Q3 24 | 1.10× | 1.82× | ||
| Q2 24 | 0.88× | 1.65× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CME
暂无分部数据
IR
| Transferred At Point In Time | $1.5B | 71% |
| Transferred Over Time | $193.0M | 9% |
| Precision And Science Technologies Segment | $183.1M | 9% |
| Acquisitions In2024 | $175.6M | 8% |
| Acquisitions In2025 | $70.8M | 3% |